ReCor Medical announced today that its Paradise ultrasound renal denervation (uRDN) system successfully reduced blood pressure in a study.
Palo Alto, California-based ReCor published primary endpoint results from its Radiance II trial in the Journal of the American Medical Association (JAMA). Results showed success for Paradise in reducing blood pressure compared to sham. Additionally, pooled analysis from multiple studies showed consistent blood pressure lowering. This took effect across a range of hypertension, including mild to moderate and resistant hypertension.
“The results of the Radiance clinical trials are meaningful in that they solidify the role of the Pa…